X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (148) 148
humans (144) 144
oncology (139) 139
female (124) 124
middle aged (85) 85
aged (77) 77
adult (72) 72
antineoplastic combined chemotherapy protocols - therapeutic use (67) 67
breast neoplasms - drug therapy (65) 65
breast cancer (61) 61
chemotherapy (61) 61
cancer (41) 41
male (41) 41
article (34) 34
aged, 80 and over (33) 33
clinical trials (32) 32
breast neoplasms - pathology (31) 31
treatment outcome (30) 30
neoplasm staging (29) 29
abridged index medicus (28) 28
antineoplastic combined chemotherapy protocols - adverse effects (28) 28
combined modality therapy (28) 28
survival (28) 28
lung neoplasms - drug therapy (27) 27
lung neoplasms - pathology (25) 25
breast neoplasms - mortality (24) 24
paclitaxel (24) 24
prognosis (24) 24
survival analysis (24) 24
chemotherapy, adjuvant (23) 23
disease-free survival (23) 23
carcinoma, non-small-cell lung - drug therapy (22) 22
tamoxifen (21) 21
women (21) 21
breast neoplasms - genetics (20) 20
research (19) 19
therapy (19) 19
cyclophosphamide - administration & dosage (18) 18
lung neoplasms - mortality (18) 18
surgery (18) 18
cisplatin - administration & dosage (17) 17
medicine & public health (17) 17
survival rate (17) 17
medicine, general & internal (16) 16
paclitaxel - administration & dosage (16) 16
carcinoma (15) 15
carcinoma, non-small-cell lung - pathology (15) 15
care and treatment (15) 15
health aspects (15) 15
risk (15) 15
risk factors (15) 15
antineoplastic agents - adverse effects (14) 14
cancer therapies (14) 14
drug administration schedule (14) 14
patients (14) 14
radiotherapy (14) 14
breast neoplasms - therapy (13) 13
cisplatin (13) 13
combination (13) 13
follow-up studies (13) 13
lung neoplasms - radiotherapy (13) 13
trastuzumab (13) 13
womens health (13) 13
adjuvant treatment (12) 12
antineoplastic agents - therapeutic use (12) 12
breast neoplasms - surgery (12) 12
carboplatin (12) 12
carcinoma, non-small-cell lung - mortality (12) 12
clinical trials as topic (12) 12
doxorubicin - administration & dosage (12) 12
lung neoplasms - therapy (12) 12
randomized controlled trials as topic (12) 12
risk assessment (12) 12
adjuvant chemotherapy (11) 11
analysis (11) 11
breast neoplasms - metabolism (11) 11
breast-cancer (11) 11
cyclophosphamide (11) 11
deoxycytidine - analogs & derivatives (11) 11
doxorubicin (11) 11
fluorouracil - administration & dosage (11) 11
postmenopausal women (11) 11
randomized-trial (11) 11
tumors (11) 11
age (10) 10
antineoplastic combined chemotherapy protocols - administration & dosage (10) 10
carcinoma, non-small-cell lung - radiotherapy (10) 10
deoxycytidine - administration & dosage (10) 10
etoposide - administration & dosage (10) 10
hematology, oncology and palliative medicine (10) 10
kaplan-meier estimate (10) 10
original reports (10) 10
patient outcomes (10) 10
prospective studies (10) 10
time factors (10) 10
carboplatin - administration & dosage (9) 9
carcinoma, non-small-cell lung - therapy (9) 9
diagnosis (9) 9
drug therapy (9) 9
expression (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 23, pp. 2269 - 2270
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9729, pp. 1871 - 1872
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9687, pp. 379 - 386
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 7/2009, Volume 101, Issue 14, pp. 984 - 992
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 21, pp. 2005 - 2014
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 5, pp. 435 - 444
The combination of anastrozole and fulvestrant — which interfere with estrogen signaling by distinct mechanisms — increases progression-free and overall... 
PHASE-III TRIAL | MEDICINE, GENERAL & INTERNAL | ONCOLOGY-GROUP | TAMOXIFEN | DOUBLE-BLIND | RANDOMIZED-TRIAL | ENDOCRINE THERAPY | POSTMENOPAUSAL WOMEN | 1ST-LINE THERAPY | HORMONAL-THERAPY | FIRST-LINE THERAPY | Triazoles - administration & dosage | Triazoles - adverse effects | Estradiol - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Nitriles - administration & dosage | Aromatase Inhibitors - adverse effects | Neoplasm Metastasis | Aged, 80 and over | Estradiol - adverse effects | Postmenopause | Adult | Female | Aromatase Inhibitors - administration & dosage | Estradiol - administration & dosage | Kaplan-Meier Estimate | Breast Neoplasms - drug therapy | Cross-Over Studies | Disease-Free Survival | Estrogen Antagonists - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Estrogen Antagonists - adverse effects | Breast Neoplasms - mortality | Aged | Nitriles - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Breast cancer | Dosage and administration | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Fulvestrant | Statistical analysis | Anastrozole | Estrogen receptors | Tamoxifen | Cancer therapies | Survival | Patients | Post-menopause | Metastases | Chemotherapy | Womens health | Aromatase | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2018, Volume 379, Issue 2, pp. 111 - 121
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 55 - 65
Summary Background The 21-gene recurrence score assay is prognostic for women with node-negative, oestrogen-receptor-positive breast cancer treated with... 
Hematology, Oncology and Palliative Medicine | INTERNATIONAL EXPERT CONSENSUS | SURVIVAL | PRIMARY THERAPY | ONCOLOGY | RECOMMENDATIONS | GENE-EXPRESSION | RISK | HIGHLIGHTS | DEATH | SIGNATURE | TUMOR-MARKER | Doxorubicin - therapeutic use | Predictive Value of Tests | Recurrence | United States - epidemiology | Breast Neoplasms - secondary | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Gene Expression Profiling | Receptors, Estrogen - analysis | Genetic Testing - methods | Cyclophosphamide - therapeutic use | Patient Selection | Fluorouracil - therapeutic use | Breast Neoplasms - chemistry | Clinical Trials, Phase III as Topic | Time Factors | Postmenopause | Adult | Female | Retrospective Studies | Risk Assessment | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Lymphatic Metastasis | Reverse Transcriptase Polymerase Chain Reaction | Breast Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Disease-Free Survival | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tamoxifen - therapeutic use | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Chemotherapy | Cyclophosphamide | Clinical trials | genomics | Breast cancer | Tamoxifen | Doxorubicin | Survival | Nodes | Post-menopause | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 2, pp. 134 - 141
A multicenter single-group trial suggests that adjuvant therapy with paclitaxel plus trastuzumab lowers the risk of relapse in women with small HER2-positive... 
OVEREXPRESSION | WOMEN | MEDICINE, GENERAL & INTERNAL | ONCOGENE | EFFICACY | SAFETY | RISK | MONOCLONAL-ANTIBODY | CHEMOTHERAPY | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - therapy | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Mastectomy, Segmental | Aged, 80 and over | Adult | Female | Receptor, ErbB-2 - immunology | Chemotherapy, Adjuvant | Paclitaxel - administration & dosage | Adenocarcinoma - chemistry | Antibodies, Monoclonal, Humanized - adverse effects | Neoplasm Recurrence, Local | Paclitaxel - adverse effects | Survival Rate | Radiotherapy | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Disease-Free Survival | Adenocarcinoma - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma - mortality | Breast cancer | Dosage and administration | Drug therapy | Risk factors | Paclitaxel | Invasiveness | Clinical trials | Congestive heart failure | Neuropathy | Cancer therapies | Survival | Patients | ErbB-2 protein | Metastases | Chemotherapy | Epidermal growth factor | Ventricle | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2015, Volume 372, Issue 10, pp. 923 - 932
Journal Article
Annals of Oncology, ISSN 0923-7534, 2013, Volume 24, Issue 9, pp. 2206 - 2223
Journal Article